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ehe Annual Congress of the European Society of Cardiol-
gy (ESC) was held in Munich, Germany from August 29
o September 3, 2008. The total attendance was 30,500
articipants from 137 different countries. Excellent congress
acilities hosted 218 pre-arranged sessions in 29 meeting
ooms (running in parallel) including several joint sessions
n collaboration with other societies (e.g., the American
ollege of Cardiology and the American Heart Associa-
ion). A total of 9,669 abstracts from 96 different countries
rom the *Aarhus University Hospital, Skejby, Aarhus, Denmark; †Department of
ardiology, Munster, Germany; ‡Department of Cardiovascular Medicine, Univer-
ity of Oxford, Oxford, United Kingdom; §Zentrum Innere Medizin, Klinik für
ardiologie und Angiologie, Hannover, Germany; Centre Hospitalier Universitaire
audois, Lausanne, Switzerland; ¶Athens University Hospital Attikon, Athens,
reece; #University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom;
*Department of Cardiology, Oskarshamm, Sweden; ††C.H.U. du Sart-Tilman,
niversite de Liege, Liege, Belgium; ‡‡Erasmus Medical Center, Rotterdam, the
etherlands; §§Universitaetsklinikum Schleswig-Holstein, Campus Luebeck, Lue-
eck, Germany;  Heraklion University Hospital, Crete, Greece; ¶¶Leiden Univer-
ity Medical Center, Leiden, the Netherlands; and the ##Royal Brompton Hospital,
ondon, United Kingdom. Dr. Kristensen has received lecture fees and is on the
dvisory board for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,
ycomed, Pfizer, and Sanofi. Dr. Casadei has received lecture fees and sponsorship
rom Boehringer, Novartis, and Bristol-Myers Squibb. Dr. Drexler has received
esearch grants, lecture fees, and is on the advisory board for Medtronic, Merck-Sharp
ohme, and Novartis. Dr. Eeckhout has received research grants from Boston
cientific, Medtronic, Abbott Vascular, B Braun, and Cordis. Dr. Filippatos has
eceived research grants from Roche Diagnostics, Brahms, Biosite, Otsuka,
igmaTau, and Medtronic. Keith Fox has received research grants, lecture fees, and
s on the advisory board for Sanofi-Aventis, Bristol-Myers Squibb, and GlaxoSmith-
line and has received research grants/honoraria from Servier. Dr. Poldermans has
eceived research grants from Merck and Novartis. Dr. Schunkert has received lecture
ees and is on the advisory board for Merck-Sharp Dohme/Essex, Novartis,
anofi-Aventis, AstraZeneca, Pfizer, and Nycomed. Dr. Vardas has received lecture
ees from Boston Scientific. Dr. Bax has received research grants from GE Health-
are, Bristol-Myers Squibb Medical Imaging, St. Jude, Medtronic, Boston Scientific,h
nd Edwards Lifesciences.
Manuscript received October 15, 2008, accepted October 16, 2008.ere submitted, and 3,532 (36%) were selected for presen-
ation, including 392 dedicated to cardiovascular imaging.
The theme of the meeting was “cardiovascular imaging.”
his topic was addressed in 56 pre-arranged sessions and 17
cientific abstracts sessions. In this document, a summary of
he most important contributions presented at the different
essions is provided.
maging
chocardiography. A large amount of studies used strain
maging in heart disease. Myocardial strain can be quanti-
ed separately in endocardial and epicardial layers using
peckle tracking 2-dimensional (2D) strain imaging. In a
ig model with different severities of ischemia, circumfer-
ntial strain was obtained in areas at risk and control areas,
oth at rest and during dobutamine infusion. Sonomicrom-
try served as the reference method. Endocardial strain was
ore severely affected by ischemia as compared with epi-
ardial strain (1). Strain can also be used to reflect the extent
f left ventricular (LV) scar formation. In a rat model,
peckle tracking 2D radial strain imaging was performed
4 h after reperfusion. The area at risk and the area of scar
ere quantified; contrast-enhanced magnetic resonance im-
ging (MRI) served as the gold standard. Segmental radial
train correlated with the transmural extent of scar on MRI
r  0.61, p  0.0001) (2). Mignot et al. (3) evaluated 147
eart failure patients and demonstrated that global longitu-
inal strain (measured by 2D speckle tracking) had superior
rognostic value as compared with conventional parameters
uch as cardiac dimensions, LV ejection fraction, LV filling
ressures, and mitral regurgitation. Ramshorst et al. (4)
valuated patients undergoing alcohol septal ablation for
ypertrophic obstructive cardiomyopathy. The authors
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December 9, 2008:2032–42 Highlights of ESC 2008 Scientific Sessionshowed that the immediate reduction in septal strain (as-
essed directly after ablation) correlated well with the
ecrease in LV outflow tract gradient at 6 months follow-up
r  0.70, p  0.01) (4).
Various studies evaluated echocardiography in valvular
eart disease. Exercise testing may be useful in asymptom-
tic patients with significant mitral stenosis. Mean pressure
radient, estimated systolic pulmonary artery pressure, and a
elative increase of pressure from rest to peak exercise were
easured. Peak pressure was frequently 60 mm Hg
ithout a difference between patients with dyspnea during
he test or asymptomatic individuals, indicating that symp-
oms during exercise testing do not predict hemodynamic
hanges (5).
In asymptomatic patients with severe aortic stenosis,
lobal longitudinal LV strain was measured by Lancel-
otti et al. (6) at rest and at peak exercise in 174 patients
nd 32 normal, age-matched control subjects. Patients
ad lower strain at rest and peak exercise. Moreover,
xercise-induced depression of global strain was more
rominent in patients who developed symptoms during
he exercise test as compared with that seen in patients
ho remained asymptomatic.
Another topic of interest was paravalvular aortic regurgi-
ation after percutaneous aortic valve replacement. The
ain determinant of paravalvular aortic regurgitation was
he aortic annular size. Detaint et al. (7) demonstrated that
orrect prosthesis sizing and accurate measurement of an-
ular dimensions are needed to minimize regurgitation;
ransthoracic echocardiography underestimated annular size
s compared with that seen with (real-time) transesophageal
chocardiography (8,9).
uclear imaging, MRI, and multislice computed tomog-
aphy (MSCT). Various studies with nuclear imaging ad-
ressed long-term outcome in patients with coronary artery
isease (CAD). Schepis et al. (10) evaluated the prognostic
alue of stress technetium-99m sestamibi single-photon
mission computed tomography (SPECT) in 415 patients
ith 3-vessel disease and previous revascularization. The
nnual cardiac event rate was 3.8% in patients with an
bnormal SPECT as compared with 0.3% in patients with
ormal SPECT (p  0.008), indicating the ability of
PECT to risk stratify patients with previous revasculariza-
ion. Galassi et al. (11) evaluated the prognostic value of
echnetium-99m tetrofosmin SPECT 4 to 6 weeks after
ncomplete revascularization of 126 patients with multives-
el CAD who underwent incomplete revascularization by
ercutaneous coronary intervention (PCI). Absence of isch-
mia was associated with excellent outcome. Tio et al. (12)
valuated 480 patients with chronic CAD using stress-rest
erfusion imaging with positron emission tomography and
13-ammonia; a reduced flow reserve was associated with
n increased event rate.
Many studies with MRI were related to the use of
ontrast-enhanced imaging to detect scar tissue. One study
ddressed the relation between scar tissue on MRI and the cccurrence of nonsustained ventricular tachycardia in 88
atients with hypertrophic cardiomyopathy (13). Patients
17%) with ventricular tachycardia on Holter monitoring
ad more extensive scar formation than those without
entricular arrhythmias (21.0 11.1% vs. 7.5 8.7% of the
V, p  0.0001). Chan et al. (14) studied the prognostic
alue of scar tissue on MRI in 269 patients with CAD, and
emonstrated that scar tissue was predominantly related to
utcome in patients with relatively preserved LV ejection
raction (40%).
MSCT is increasingly used for noninvasive angiography,
nd recent studies focus on its prognostic value. Aldrovandri
t al. (15) obtained 2-year follow-up data in 310 patients
ith suspected CAD who underwent MSCT calcium scor-
ng and noninvasive angiography. A completely normal
SCT examination (zero calcium score and normal angio-
ram) had a 0% event rate; of note, the MSCT findings
ere superior for outcome over clinical risk factors. Had-
mitzky et al. (16) reported similar findings with a negative
redictive value of 99.2% for MSCT angiography in 645
atients who were followed-up for almost 4 years. This high
egative predictive value makes MSCT extremely useful for
uling out CAD, and screening of asymptomatic patients
as been suggested. Chang et al. (17) demonstrated, in a
arge population (n  1,043), that screening of asymptom-
tic individuals was useful to rule out CAD, but resulted in
significant increase of additional diagnostic procedures
nd even revascularizations in asymptomatic patients with
therosclerosis on MSCT. According to this observation,
nd several other studies, the presence of atherosclerosis
oes not necessarily imply ischemia. This has increased
nterest in so-called hybrid imaging: integration of MSCT
or atherosclerosis assessment and SPECT or positron
mission tomography imaging for ischemia assessment.
ujitaka et al. (18) evaluated 126 patients with suspected
AD and demonstrated an improvement in specificity (97%
s. 60%, p  0.001) and positive predictive value (96% vs.
6%, p  0.001) without significant changes in sensitivity
93% vs. 98%, p  NS) and negative predictive value (94%
s. 98%, p  NS) compared with that seen with MSCT
lone. Another study used the combination of MSCT
ngiography and perfusion imaging with MRI (19), show-
ng similar results.
The major limitation of MSCT is the radiation burden,
nd a snapshot pulse protocol was proposed (20); a signif-
cant reduction in radiation exposure with this protocol was
hown as compared with that seen with the conventional
pproach.
alvular Heart Disease
he effect of statins on the progression of aortic stenosis was
resented in the SEAS (Simvastatin and Ezetimibe in
ortic Stenosis) trial (21). A total of 1,873 patients with
ild-to-moderate aortic stenosis were randomized to theombination of simvastatin (40 mg) and ezetimibe (10 mg)
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Highlights of ESC 2008 Scientific Sessions December 9, 2008:2032–42ersus placebo. The primary study end point was major
ardiovascular events, which was the composite of events
ssociated with aortic sclerosis and atherosclerotic disease.
he combination treatment resulted in a 61% low-density
ipoprotein (LDL) cholesterol lowering that was sustained
uring the 4-year study period. However, no effect was
oted on the incidence of the study end point (hazard ratio
HR]: 0.96, 95% confidence interval [CI]: 0.83 to 1.12).
esides the failure of reduction in progression of aortic
clerosis, serious concern was raised because of the increased
ncidence of cancer in the treatment group (11.1% vs. 7.5%,
 0.01). This unexpected finding could, however, not be
onfirmed in reanalysis of data from 2 larger trials (n 
0,617 patients) using the same medication (22).
Interestingly, Antonini-Canterin et al. (23) performed a
etrospective analysis of 1,046 patients with aortic sclerosis/
tenosis with a mean follow-up of 5.6  3.2 years. The
uthors showed that 309 patients treated with statins had
ignificantly slower progression rates as compared with
ontreated patients when aortic sclerosis or mild stenosis
as present. In patients with moderate aortic stenosis, statin
herapy did not make a difference on progression of stenosis
everity.
In an interesting animal study of hyperlipidemic apoE-
nockout mice, uremia was shown to induce aortic
tenosis (24). This uremia-induced aortic valve thicken-
ng could be inhibited by the use of angiotensin-
onverting enzyme (ACE) inhibition. Herrmann et al.
25) studied 58 patients with aortic stenosis who under-
ent surgical valve replacement and also myocardial
iopsy. Performing echocardiography and MRI before, 2
eeks, and 9 months after surgery, the authors demon-
trated that scar tissue on MRI as well as longitudinal
ystolic LV function correlated with the histological
egree of fibrosis. Significant fibrosis was closely related
o an unfavorable post-operative outcome.
The outcome of transfemoral aortic valve implantation
as shown to improve with further increase in experience.
omparing 112 patients in their “18-F Safety and Efficacy
rial” with 282 registry patients, the Corevalve Investigators
26) reported a significant reduction in intervention time
nd lower mortality rates. The first-in-man experience with
new transfemoral implantable stentless aortic valve that
an be repositioned and also is fully retrievable was reported
y Schofer et al. (27). A permanent implant was achieved in
3 of 17 (76%) high-risk patients with 1 death, 1 stroke, and
surgical conversion; hemodynamic and symptomatic re-
ults were adequate. Weisenberg et al. (28) followed 262
atients with moderate aortic regurgitation for 42  32
onths. Progression to severe disease was observed in 6.9%
1.9% per year) with a need for surgery in 0.3% per year.
rogression rate was slower in patients with valve pathology
3.7% per year) compared with that seen in patients with
ortic root pathology (1.4% per year) suggesting that valve
eplacement for moderate regurgitation caused by valve sathology may not be required at the time of other cardiac
urgery.
eart Failure
he BEAUTIFUL (Morbidity-Mortality Evaluation of the
f Inhibitor Ivabradine in Patients With Coronary Disease
nd Left Ventricular Dysfunction) trial evaluated the prog-
ostic value of baseline heart rate and intervention using a
ure heart rate modulator, ivabradine, in patients with
AD and LV dysfunction (29,30). Ivabradine is a selective
eart-rate–lowering agent, acting on the sinus node without
ffecting other cardiac functions. Baseline heart rate is
nown to be a prognostic marker for cardiac events in
atients with CAD. There is a continuous increase in risk
ith heart rates above 60 beats/min, though no specified
eart rate threshold is defined, nor is it known at which
eart rate intervention may improve long-term outcome. A
otal of 10,917 individuals with CAD and reduced LV
unction were randomized for ivabradine, 5 mg twice daily,
ollowed by an up-titration to 7.5 mg twice daily if heart rate
emained above 60 beats/min after 2 weeks versus placebo.
atients received treatment in addition to medical therapy
ncluding beta-blockers in 87% and ACE inhibitors in 90%.
he primary study end point was the composite of cardio-
ascular mortality and hospitalization for myocardial infarc-
ion (MI) or heart failure. The median duration of
ollow-up was 19 months. Ivabradine failed to reduce the
ncidence of the primary study end point (HR: 1.0, 95% CI:
.91 to 1.1, p  0.94). Baseline heart rate, analyzed as a
ontinuous variable, showed to be an important prognostic
arker; patients with a heart rate over 70 beats/min had a
ignificantly higher risk of cardiovascular mortality (34%,
 0.004). Analysis of a pre-specified subgroup of patients
ith a baseline heart rate over 70 beats/min showed a
ignificant reduction of the coronary end points acute MI
nd coronary revascularization (36%, p  0.001 and 30%,
 0.016, respectively). Importantly, the frequency of
erious side effects was similar between the treatment
roups, 22.5% versus 22.8%.
The results of rosuvastatin therapy in patients with
hronic heart failure were reported within the GISSI-HF
Gruppo Italiano per lo Studio della Sopravivenza
ell’Infarto Miocardico–Heart Failure) trial (31). A total of
,574 patients with New York Heart Association (NYHA)
unctional class II to IV heart failure from any cause were
andomized to rosuvastatin 10 mg daily or placebo. Study
nd points were mortality and hospitalization for cardiovas-
ular reasons during a median follow-up of 3.9 years.
reatment was prescribed in addition to current therapy:
eta-blockers in 62% and ACE inhibitors in 77%. No
ifference was observed in the study end point between the
treatment groups (HR: 1.01, 95% CI: 0.91 to 1.1, p 
.90). In contrast to the failure of rosuvastatin to improve
utcome in heart failure patients were the results of fish oil
upplementation in these patients (32). Within the
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December 9, 2008:2032–42 Highlights of ESC 2008 Scientific SessionsISSI-HF trial, 7,046 patients were randomized to 1.0 g
-3 polyunsaturated fatty acids or placebo in addition to
ptimal medical therapy; similar study end points and
uration of follow-up were applied as described in the
receding text. Fish oil supplementation resulted in a
ignificant reduction of the study end point (HR: 0.92, 95%
I: 0.85 to 0.99, p  0.009).
The issue of how to manage inflammatory cardiomyop-
thy (virus negative myocarditis with evidence of inflamma-
ion on biopsy) was investigated in a trial by Frustraci et al.
33) comparing prednisone/azathioprine with placebo. A
otal of 85 patients (mean age 42  15 years) were included
ith myocarditis, LV ejection fraction 45%, and negative
yocardial polymerase chain reaction for viruses. Surpris-
ngly, 6 months of prednisone/azathioprine treatment re-
ulted in a dramatic improvement in LV ejection fraction,
hich was not observed in the placebo arm. Thus, immu-
osuppression in patients with virus-negative inflammatory
ardiomyopathy appears to be effective and should be
trongly considered.
Can a disease-managing program (telephone-based mon-
toring and education by specialized heart failure nurses)
mprove outcome and hospitalizations in chronic heart
ailure patients? A large trial addressed this issue and used
he end points of time to first event (all-cause mortality,
ospitalization), days alive and out of hospital, NYHA
unctional class, quality of life, and ESC guideline adher-
nce (34). This study with more than 700 patients and 6
onths follow-up revealed that this specific nurse-based
anagement of disease program has the potential to reduce
ortality by 43%, with also a significant improvement in
orbidity.
Cardiac resynchronization therapy (CRT) is now estab-
ished and indicated in patients with symptomatic heart
ailure (NYHA functional class III to IV), depressed LV
jection fraction, and wide QRS complex despite optimized
edical therapy. The REVERSE (Resynchronization Re-
erses Remodeling in Systolic Left Ventricular Dysfunc-
ion) trial conducted by Linde (35) addressed whether CRT
s also beneficial in less symptomatic patients (NYHA
unctional class I to II), in whom the main goal would be
revention of heart failure progression. Patients with
YHA functional class I to II, wide QRS complex (120
s), and depressed LV ejection fraction (40%) on opti-
ized medical therapy were enrolled. The primary end
oint was a clinical composite score including all-cause
ortality, heart failure hospitalization, and progression of
eart failure/NYHA functional class. The interim 18-
onth follow-up data of the European arm indicate that
enefits from CRT in NYHA functional class I to II
atients are sustained over time, and CRT may help prevent
eart failure progression.
Finally, current generations of CRT devices provide
ontinuous measurement of intrathoracic impedance to
onitor changes in lung fluid status, which permits for earlyetection of heart failure either by device alarm or by transferring alert to physicians via the internet. A large study
nvolving more than 500 patients has assessed the accuracy
f this system as well as the practicality of internet-based
lert transfer to the caring physician. The observations are
ncouraging, even though false positive alerts and technical
ssues are still to be overcome (36,37).
cute Cardiac Care
he European Resuscitation Council guidelines recom-
end mild hypothermia for 24 h after cardiopulmonary
esuscitation to improve survival and neurological outcome.
owever, intravascular cooling devices are expensive and
ot available in all hospitals. A retrospective analysis from
2 resuscitated patients showed that infusion of large
olume, ice-cold saline is effective, safe, and inexpensive for
he induction of neuroprotective hypothermia (38). In the
ame guidelines, administration of atropine is recom-
ended. In a prospective, multicenter, observational trial,
he effects of atropine have been assessed in 7,443 adults
atients with asystole or pulseless electrical activity (39).
he primary end point was a favorable neurological out-
ome at 30 days after cardiac arrest. Administration of
tropine improved rate of return of spontaneous circulation,
ut did not increase the frequency of favorable neurological
utcome. Moreover, in the group with pulseless electrical
ctivity, atropine was associated with a trend toward worse
urvival.
It has been recommended that patients with ST-segment
levation myocardial infarction (STEMI) should stay in the
ntensive cardiac care unit for 48 h (40). However, in some
enters, low-risk STEMI patients who have undergone
uccessful primary PCI are admitted to a step-down care
nit. This is supported by a study in 227 STEMI patients in
illip class I, treated with primary PCI. This low-risk group
id not benefit from intensive cardiac care unit stay (41).
oreover, in another study, 45.5% of 471 STEMI patients
reated with primary PCI were discharged after a 48-h
ospitalization. Early discharge in these selected low-risk
atients (Thrombolysis In Myocardial Infarction flow grade
with resolution of ST-segment elevation and good or
oderately depressed LV function without arrhythmias after
uccessful reperfusion) was associated with 0% mortality at 30
ays and 0.9% during follow-up (283  148 days) (42).
nterventional Cardiology
nd Peripheral Vascular Disease
uring the main session on drug-eluting stents (DES)
afety “2 years after Barcelona,” the importance of large scale
egistries was stressed. Well-conducted registries reflect real
ife practice, which is often excluded from randomized trials.
endiz et al. (43) presented the OLYMPIA registry,
ncluding 22,345 PCI patients treated with the TAXUS
iberté stent. Expanded use (beyond simple stenting) was
erformed in 74.9% of cases. At 1-year follow-up, the stent
hrombosis rate was 0.8% while the total adverse events rate
(
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Highlights of ESC 2008 Scientific Sessions December 9, 2008:2032–42including the need for reintervention) was 3.8%. The
erman Cypher registry (44) reported on 11,070 PCI cases
t 6 months follow-up. The registry population presented
ith more complex pathology (42% acute coronary syn-
romes [ACS], 70% multivessel disease), and the overall
dverse events rate was, therefore, 10.9%. Both strategies
eflect the current opinion, that DES provides sustained
afety in a broad range of indications. Efficacy, however,
epends on anatomy as the need for reintervention increases
ith lesion complexity.
Sirbu et al. (45) used different intravascular imaging
odalities and thrombus aspiration analysis to demonstrate
echanisms of late stent thrombosis in patients: positive
emodeling up to aneurysm formation, uncovered stent
truts, aggressive restenosis, and hypersensitivity reactions
ere reported to be important. In line with this, Manterola
t al. (46) documented 1.25% of coronary aneurysms during
ystemic angiographic follow-up in 1,197 patients treated
ith DES. There were significantly more adverse events in
hese patients, indicating a need for careful follow-up.
The SYNTAX (Synergy Between PCI and CABG) trial
as one of the major studies presented by Mohr and Serruys
47). A heart team (cardiologist and surgeon) evaluated
atients with multivessel disease for the amenability of both
evascularization strategies. Eligible patients were random-
zed to coronary artery bypass grafting (CABG) or mul-
ivessel PCI with the TAXUS stent; uneligible patients
ere followed in a CABG or PCI registry. This multicenter
rial involving 85 European and U.S. sites was characterized
y very few exclusion criteria, consisting of previous or
lanned cardiac interventions and/or acute infarction. In
ddition to the classical surgical Euroscore, the investigators
ad developed a PCI risk score called the SYNTAX score.
he role of this purely anatomical score needs further
nvestigation in the future. The primary end point (adverse
vents being a composite of all-cause death, infarction,
erebrovascular accident [CVA], and repeat intervention at
year) as well as the registry results were presented. At 1
ear, adverse events were 12.1% for CABG as compared
ith 17.8% for PCI (p  0.0015). In terms of overall safety
death, CVA, MI), there was no difference between CABG
nd PCI (7.7% vs. 7.6%, p  0.98). Therefore, the differ-
nce in the primary end point was mainly driven by a higher
eed for reintervention in the PCI group: 5.9% in the
ABG group versus 13.7% in the PCI group (p  0.0001).
urther analysis indicated a higher incidence of CVA in the
ABG group (5.9% with CABG vs. 13.7% with PCI, p 
.0001). Symptomatic graft occlusion (3.4%) and stent
hrombosis (3.3%) were similar. Interestingly, a subgroup
nalysis in 138 patients with left main disease and additional
ingle-vessel involvement showed no difference in primary
nd point at 1-year follow-up. Finally, the CABG registry
howed comparable adverse event rates at 1 year (8.8%)
espite the presence of a much higher SYNTAX score (37.8
13.3 vs. 29.1  1.4 for the randomized CABG patients).
he key messages from the SYNTAX trial are as follows: 1) Cqual safety of both revascularization procedures; 2) signif-
cant difference in the primary end point driven by a higher
eed for reintervention in the PCI group; and 3) lesion
omplexity, as assessed by the SYNTAX score, should guide
he physicians in terms of the optimal revascularization
trategy since this score has no impact on adverse outcome
fter CABG.
The CARDIA (Coronary Artery Revascularization in
iabetes) trial randomized 510 diabetic individuals with
ultivessel disease (excluding left main disease) to PCI or
ABG and was presented by Kapur (48). The primary end
oint was a composite similar to the SYNTAX study but
xcluding the need for reintervention. At 1 year, there was
o difference in terms of death, MI, and stroke (CABG
0.2% vs. PCI 11.6%, p  NS). However, there was again
higher need for reintervention with PCI (CABG 2.0% vs.
CI 9.9%, p  0.001). The CARDIA study refined the
revious conclusions of the SYNTAX study on the safety of
oth PCI and CABG to diabetic patients specifically, but
urther follow-up is needed.
Finally, the LEADERS (Limus Eluted From a Durable
ersus Erodable Stent) trial, investigating the role of new
tent technology (biodegradable polymer [within 6 to 9
onths] with biolimus on top), was presented by Wind-
cker et al. (49). A total of 1,707 “all comer” patients were
andomized to this stent versus a classical sirolimus-eluting
tent. At 9 months, there was no difference in the primary
nd point of death, MI, and need for reintervention (bioli-
us: 9.2% vs. sirolimus: 10.5%, p  0.88). This study
emonstrates efficacy at 9 months as well as safety expected
o be maintained because of the principle of a DES turning
nto “bare metal” after 6 to 9 months. However, long-term
ollow-up will be crucial to confirm this hypothesis.
The influence of statin use on the incidence of perioper-
tive myocardial ischemia, myocardial ischemia, and cardiac
eath was evaluated in patients undergoing high-risk major
ascular surgery. Cardiac events are the major cause of
erioperative morbidity and mortality, and a titrated low-
osage bisoprolol regimen has been shown to effectively
educe post-operative cardiac events in these patients. How-
ver, up to 50% of all fatalities are related to coronary plaque
upture due to the stress of surgery. Poldermans et al. (50)
andomized 497 statin-naïve patients to fluvastatin ex-
ended release 80 mg daily or placebo beginning 37 days
efore surgery on top of optimal medical therapy including
isoprolol in all patients. The primary study end point was
he incidence of electrocardiographic-assessed ischemia and
roponin release during the first 30 days after surgery.
luvastatin extended release was chosen to bridge the early
eriod after surgery in which patients can frequently not
ake oral medication, the only prescription form of statins.
luvastatin use resulted in a significant reduction of the
rimary study end point (odds ratio: 0.53, 95% CI: 0.32 to
.88, p  0.02). Patients on fluvastatin therapy showed a
ignificant reduction of LDL cholesterol, high sensitive
-reactive protein, and interleukin-6 levels. This systemic
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ssociated with the improved post-operative outcome in this
igh-risk population, with an estimated number of patients
eeded to treat of 13 to prevent myocardial ischemia in the
rst 30 days after surgery.
CS
ew information from studies presented at ESC 2008 added
o the evidence for the timing of interventional treatment and
djunctive antiplatelet and antithrombin therapy in conjunc-
ion with primary PCI. These complement the recommenda-
ions of the new guidelines for the management of STEMI
resented at the meeting by Van de Werf (51).
The On-Time 2 (Ongoing Tirofiban in Myocardial
nfarction Evaluation) study presented by van’t Hof (52)
ested the impact of pre-hospital administration of a glyco-
rotein IIb/IIIa inhibitor (tirofiban) or placebo in patients
reated with aspirin and 600 mg clopidogrel. Survival free of
ajor adverse clinical events (combination of death, re-MI,
rgent target vessel revascularization, stroke, and major
leeding) was improved by pre-hospital tirofiban treatment
p  0.04). There was improved resolution of ST-segment
levation, and the frequency of aborted infarction was
ncreased (odds ratio: 1.38, p  0.04). Interestingly, the
enefits were especially marked in those presenting within
5 min of symptom onset. Although the study is not
efinitive, it raises important questions about the timing of
djunctive antithrombotic therapy in STEMI.
The HORIZONS AMI (Harmonizing Outcomes with
evascularIZatiON and Stents in Acute Myocardial Infarc-
ion) trial (n  3,602 patients) tested bivalirudin mono-
herapy (with provisional glycoprotein IIb/IIIa usage)
gainst unfractionated heparin and systematic glycoprotein
Ib/IIIa blockers (all underwent primary PCI). Stone et al.
53) reported that net adverse clinical events (all-cause
eath, reinfarction, ischemic target vessel revascularization,
troke, and major bleeding) were reduced with bivalirudin
from 12.2% to 9.3%), and the largest component was the
eduction in major bleeding (from 8.4% to 5.0%). Thirty-
ay mortality was lower with bivalirudin (3.1% vs. 2.1%).
A time-dependent covariate-adjusted Cox model (C
tatistic 0.87) was used to relate the impact of adverse events
o 30-day mortality. Although the frequency of reinfarction
as higher than major bleeding, the latter was more
ommon, and hence the number of deaths attributable was
igher for major bleeding than for MI (20.4 vs. 9.0).
efinite stent thrombosis had approximately 4.5 attribut-
ble deaths.
In the TRITON–TIMI 38 (Trial to Assess Improvement
n Therapeutic Outcomes by Optimizing Platelet Inhibi-
ion–Thrombolysis In Myocardial Infarction 38) study,
rasugrel versus clopidogrel was tested in patients with ACS
ith the study drug administered at the time or shortly after
CI. At ESC 2008, Montalescot presented the results for
TEMI patients (n  3,534). Approximately two-thirds of datients (69%) were treated with primary PCI, and the
emainder had subsequent PCI. Adjunctive glycoprotein
Ib/IIIa treatment was given in 60% to 64% of all cases. The
rimary end point (death, MI, stroke at 15 months) was
educed with prasugrel (10.0% vs. 12.4%, HR: 0.79) with no
xcess in major bleeding. The absolute difference was 3%
uring the very early phase of the trial and 2.4% at
5-month follow-up. Considering individual end points,
ignificant differences were seen for MI and stent throm-
osis. For the first time in a large trial (TRITON–TIMI
8), Morrow et al. (54) presented the MI outcomes using
he newly introduced Global Definition of Myocardial
nfarction and showed highly significant differences in favor
f prasugrel for spontaneous and procedure-related MIs.
A coagulation substudy of the OASIS 5 (Organisation to
ssess Strategies for Ischaemic Syndromes-5) trial showed
ew insights into the difference in efficacy and bleeding
etween fondaparinux and enoxaparin (lower anti-Xa activ-
ty with fondaparinux), and raised the question: “is less
etter?” (55).
In contrast to pre-clinical studies, human trials to limit
eperfusion injury have been largely unsuccessful. The
.I.R.E. (FX06 in Ischemia Reperfusion) study presented
y Atar et al. (56) tested a novel small peptide derived from
he human fibrin sequence (FX06) in patients undergoing
rimary PCI for STEMI. Outcomes were assessed with
ontrast-enhanced MRI. The primary outcome was not
ifferent (total scar tissue), but the necrotic core was
ignificantly reduced. This observation may encourage the
evelopment of a larger trial.
The APPRAISE-1 (APixaban for the Prevention of
cute Ischemic and Safety Events) trial presented by
lexander et al. was the first presentation of a phase 2 study
xamining an oral anti-Xa inhibitor for secondary preven-
ion after ACS. There were efficacy trends in favor of
pixaban (2.5 mg twice daily or 10 mg once daily) and a dose
elationship with bleeding (higher bleeding with apixaban
0 mg vs. 2.5 mg vs. placebo), especially in patients who also
eceived clopidogrel. This finding may have important
mplications for ongoing trials involving anti-Xa inhibitors,
oth in ACS and in atrial fibrillation (AF).
ypertension and Risk Factors for CAD
he importance of life-style modification for risk reduction
as emphasized by Erbs et al. (57). These investigators
emonstrated that obesity in children was associated with a
ecrease in circulating endothelial progenitor cells. In con-
rast, physical exercise as demonstrated in children visiting a
igh school with intensive physical activity programs or
thers who underwent a training program displayed a
arked rise in these vascular protective cells.
Hitherto unknown risk factors may modulate the proba-
ility of recurrence of vascular events. Pasterkamp et al. (58)
tudied the composition of carotid plaque material obtained
uring endarterectomy. Depending on the osteopontin
l
p
6
f
o
l
t
a
s
m
N
p
a
i
i
I
e
a
(
a
i
t
(
s
c
i
E
d
(
o
r
T
E
m
T
f
t
P
W
n
g
a
t
N
b
t
n
f
s
t
h
q
t
t
e
h
w
t
h
e
v
a
H
b
e
t
e
e
m
r
r
A
G
w
w
f
i
a
n
r
d
o
c
m
e
n
t
m
C
t
o
a
t
a
a
a
i
w
2038 Kristensen et al. JACC Vol. 52, No. 24, 2008
Highlights of ESC 2008 Scientific Sessions December 9, 2008:2032–42evels as well as other predictive markers expressed in the
laque, future cardiovascular events varied between 10% and
0% as analyzed in more than 600 patients prospectively
ollowed for 3 years. At present, it is unclear whether
steopontin is causally involved in triggering further vascu-
ar events or, to the contrary, osteopontin is rather a marker
hat signals unstable plaques in various vascular territories.
A much discussed novel risk factor is the lipoprotein-
ssociated phospholipase A2. Previous genetic research
uggested that DNA variants associated with higher enzy-
atic activity also associate with an increased risk for MI.
ow a placebo-controlled study in patients with CAD
resented by Wijns et al. (59) suggests that a lipoprotein-
ssociated phospholipase A2 inhibitor, darapladib, admin-
stered for 1 year stops the progression of the necrotic core
n coronary plaques. This secondary end point of the
BIS-II (Integrated Biomarker and Imaging Study II) study
ncourages further development of this anti-inflammatory
gent in patients with atherosclerosis.
Some disappointment came from the TRANSCEND
Telmisartan Randomized Assessment Study in ACE Intoler-
nt Subjects With Cardiovascular Disease) study, which stud-
ed 6,000 patients intolerant to an ACE inhibitor on either
elmisartan or placebo (60). Surprisingly, the primary end point
i.e., the combination of cardiovascular death, infarction,
troke, and/or heart failure hospitalization) was not signifi-
antly different in the 2 groups. In contrast, the end point used
n the recently published HOPE (Heart Outcomes Prevention
valuation) study (cardiovascular death, infarction, and stroke)
isplayed a significant, 13% decrease in the telmisartan group
61). Given the profound effect of ramipril in the same group
f patients as studied in the HOPE trial group, equivalence of
amipril and telmisartan in the ONTARGET (Ongoing
elmisartan Alone and in Combination With Ramipril Global
ndpoint Trial) study (62), it is puzzling to see the, at best,
odest effect of telmisartan as compared with placebo in the
RANSCEND study. This certainly applies to hospitalization
or heart failure since this end point was not prevented at all by
elmisartan in the TRANSCEND study.
revention
ithin the field of cardiovascular prevention interesting
ew findings were presented. Grundtvig et al. (63) reported
ender-based differences in the effect of smoking: a first
cute MI occurs 14.4 years more prematurely in women
han in men when compared with that seen in nonsmokers.
ormal weight obesity, defined as normal weight and high
ody fat content, is found in 1 of 5 persons. It contributes
o a 3.6-fold increased risk for cardiac death in women but
ot in men (64).
The winning abstract of the Young Investigator Award
or population sciences was presented by Fosboel et al. (65),
howing increased HRs for MI and death associated with
he use of nonsteroid anti-inflammatory drugs among lealthy individuals. Based upon this finding, the authors
uestioned the free over-the-counter sale of these drugs.
The metabolic syndrome is associated with a reduction of
he anti-inflammatory properties of high-density lipopro-
ein cholesterol. German researchers showed that 8 weeks of
xercise training restored the vasoprotective properties of
igh-density lipoprotein although the effect was lost after 8
eeks of nonactivity (66). Four weeks of training restored
he catabolic-anabolic imbalance in the skeletal muscle of
eart failure patients, thus providing a further rationale for
xercise training (67).
Olsen et al. (68) showed that markers of subclinical
ascular damage (urine albumin/creatinine ratio, carotid
rtery ultrasound, and pulse wave velocity) may improve the
eartScore risk stratification and thereby reduce the num-
er of candidates for primary prevention up to 45%.
Daily physical activity by using the stairs instead of
levators at work contributes to cardiovascular prevention: at
he Geneva University Hospital, sedentary healthy employ-
es used the stairs during a 12-week period (69). Positive
ffects were noted on VO2max, waist circumference, fat
ass, blood pressure, and LDL cholesterol. However, after
eturning to the sedentary life-style, most of these beneficial
esults were lost within 3 months.
rrhythmias and Pacing
enetics in arrhythmias is a continually developing field, in
hich new discoveries, mainly of mutations, are associated
ith poorly understood clinical entities. In a 3-generation
amily with long QT syndrome and familial AF, a mutation
n SCN5A, identified for the first time, showed the genetic
ssociation between these 2 clinical entities (70). Another
ovel mutation in KCNE3 was shown to reduce the
epolarizing potassium current and cause long QT syn-
rome (71). Further genetic analysis showed that CRT not
nly corrects mechanical dyssynchrony, but also causes
hanges in regional gene expression (72).
Various studies were presented on new technology in
anagement of AF; 2 centers presented their first experi-
nce on the use of irrigated tip catheters for magnetically
avigated remote pulmonary vein isolation. Both concluded
hat the technique, in combination with electroanatomical
apping, is safe, effective, and has a high success rate.
ompleteness and continuation of mitral isthmus conduc-
ion block was easily achieved and rarely required cross-
ver to manual or solid magnetic catheters (73,74). In
ddition, Badger et al. (75) showed that imaging scar
issue with MRI may be useful in detection of gap lesions
fter failed pulmonary vein isolation.
With regard to preventing esophageal injuries during AF
blation, 20 consecutive patients received circumferential
blation using irrigated tip catheters, while continuous
ntraesophageal temperature monitoring was performed
ith the use of a multisensor probe covering most of theength of the posterior left atrium. With an intraesophageal
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eal mucosa was observed (76). Finally, for patients with
aroxysmal AF, anatomical ganglionate plexi ablation ap-
ears to be highly effective and safe, as well as satisfactory in
erms of the long-term outcome (77).
Various clinical trials and registries on AF were also
resented. In the AF-CHF (Atrial Fibrillation–Congestive
eart Failure) trial, 2 treatment options were compared:
aintenance of sinus rhythm (rhythm control) versus con-
rol of the ventricular heart rate (rate control) in patients
ith AF and LV dysfunction (78). The primary study end
oint was cardiovascular death during a mean follow-up of
7 months. A total of 1,376 patients were randomized to
ardioversion or medical therapy. There was no difference in
utcome; HR in the rhythm-control group: 1.06, 95% CI:
.86 to 1.30, p  0.59. The effect of the treatment option
ight have biased outcome; in the rhythm control group,
8% of the patients had a reoccurrence of AF during
ollow-up, while in the rate control group the treatment
argets were achieved in more than 80%. This under-
cores the need for effective new drugs and ablation
echniques to restore sinus rhythm in patients with AF. It
as concluded that in patients with heart failure, rate
ontrol is the preferred strategy, while rhythm control
hould be only considered in those with worsening of
eart failure symptoms.
The significance of very early and early recurrences of AF
fter pulmonary vein isolation was investigated by Neumann
t al. (79); the authors noted that 45% of patients with very
arly AF recurrences had no further relapses during long-
erm follow-up. The researchers suggested that repeat
blation procedures should be deferred for at least 3.5
onths after pulmonary vein isolation.
In another registry, very late relapses of paroxysmal AF
ere studied after pulmonary vein isolation (80). A database
f 827 patients treated with pulmonary vein isolation for
aroxysmal AF was screened for 7 years. Overall, 10 patients
1.2%) were identified with AF relapse 12 months after
he initially successful ablation. Late AF relapse occurred
.05  0.73 years after the initial ablation. In these patients
epeat isolation appeared to be only moderately effective.
In a post hoc analysis of the ATHENA (A Placebo-
ontrolled, Double-Blind, Parallel Arm Trial to Assess the
fficacy of Dronedarone 400 mg bid for the Prevention of
ardiovascular Hospitalization of Death From Any Cause
n Patients With Atrial Fibrillation/Atrial Flutter) trial
resented by Connolly et al., the antiarrhythmic agent
ronedarone was associated with a 34% drop (p  0.027) in
djusted risk of stroke compared with that seen with placebo
ver a follow-up period of 21  5 months.
This reduction occurred in patients who were already
eceiving appropriate antithrombotic therapy. The ATHENA
rial had already shown a 24% decline (p  0.001) in the
ime to first cardiovascular hospitalization or any-cause
eath, which was its primary end point, as well as reductionsn risk of cardiovascular mortality (29%, p  0.034), cardiovascular hospitalizations (25%, p  0.001), and ar-
hythmic death (45%, p  0.01).
In the field of CRT, new technology also offers a wider
ange of possibilities, both in placement of the LV lead and
n the long-term follow-up of patients. Taborsky et al. (81)
resented a magnetically guided approach for LV lead
mplantation, based on image integration of angiography
nd 3D computed tomographic reconstruction of the coro-
ary sinus. Remote device monitoring and heart failure
anagement in CRT-implantable cardioverter-defibrillator
atients, with the use of new devices produced by advanced
echnology that can be reviewed by clinicians on an
nternet-accessible website, has proved to be an evolving
ew methodology (82).
Two substudies from the CARE-HF (CArdiac REsyn-
hronication in Heart Failure) trial were presented. The first, a
econdary analysis of 302 patients with mean age of 75 years,
howed that in elderly patients with moderate or severe heart
ailure and markers of cardiac dyssynchrony, CRT has a
ubstantial effect on morbidity and mortality (83). The second
ubstudy analyzed the effects of CRT on long-term quality of
ife, length of hospital stay, and survival and confirmed that the
nitial, short-term improvement in quality of life with CRT
as sustained at long-term follow-up (84).
A PROSPECT (PRedictor Of reSPonsE to Cardiac
esynchronization Therapy) substudy presented interest-
ng, though preliminary, results of CRT in patients with
narrow QRS complex and LV dyssynchrony. The
ajority of patients improved in terms of clinical criteria,
ogether with a significant reduction in LV end-diastolic
imension (85).
Finally, an interesting registry, Credit Heart Failure,
howed that in a total of 3,148 patients there was a clear
iscrepancy between the number eligible for CRT or im-
lantable cardioverter-defibrillator therapy and the actual
requency of device implantations (86). The authors noted
hat only 4.3% of the patients who met the SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial) study
riteria received a device during the recording period.
asic Science
enetic modifiers and environmental factors influencing
ene expression and expressivity are increasingly called into
lay when attempting to explain the variable relationship
etween a gene mutation and the associated clinical pheno-
ype. For example, auxiliary -subunits of the cardiac
odium channel are known to modulate the channel expres-
ion at the cell surface as well as the channel’s gating
roperties and voltage dependence; through these mecha-
isms, mutations in the gene encoding 1 transcripts appear
o be sufficient to produce an arrhythmogenic phenotype in
umans. By the same token, strain-dependent differences in
he expression of the 4 ancillary subunit markedly influ-
nce the arrhythmogenic/conduction phenotype in mice
arrying a loss of function mutation in the sodium channel
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Highlights of ESC 2008 Scientific Sessions December 9, 2008:2032–42ubunit that is associated with Brugada syndrome in hu-
ans (87). These studies suggest that variability in the
xpression of genetic modifiers may be as important as the
dentification of the culprit gene mutation in guiding the
anagement and risk stratification of these patients.
More on the theme of “regulation” was provided by a
umber of studies on the burgeoning roles of micro-RNAs.
hese short, noncoding segments of RNA are now widely
ecognized as key post-transcriptional regulators of gene
xpression, participating in the control of almost every
ellular process. In the cardiovascular system, Condorelli
88) reported that micro-RNAs regulate cardiac develop-
ent, myocardial excitability, and post-natal growth, and
bdellatif (89) reported that micro-RNA also mimics the
yocardial response to hypoxia and ischemic pre-
onditioning. Importantly, inhibition of specific micro-
NAs can be exploited for therapeutic purposes, as illus-
rated by the beneficial effect of antagonizing micro-RNA
1 in an animal model of pressure overload-induced LV
ypertrophy and failure (90). It is now clear that what is
lost in translation” is not “lost in transcription,” and
iscovery of the multivarious wonders of noncoding DNA
nd its transcribed products will dominate basic and trans-
ational research for many years to come.
The genome-wide hunt for variants associated with
remature CAD continues to yield exciting and provocative
ndings (91,92). The now vastly replicated association
etween variants on chromosome 9p21.3 and premature
AD (93) remains mechanistically elusive in its ability to
redict coronary events and angiographic severity of CAD
ndependent of known risk factors (94–96). The possibility
f unearthing new targets for the treatment and prevention
f CAD seems now tantalizingly close. An excellent exam-
le of interdisciplinary research generating true innovation
as provided by studies pioneering applications of nano-
edicine and molecular imaging in animal models of
therosclerosis (97–100). The application of these tech-
iques in clinical practice will open a new dimension in the
iagnosis and staging of disease processes as well as deliver
nprecedented insights into the effect of therapeutic inter-
entions in individual patients.
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